Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients

@inproceedings{Akaza2015RealworldUO,
  title={Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients},
  author={Hideyuki Akaza and Seiji Naito and Naomi Ueno and Kouji Aoki and Hiroyuki Houzawa and Susan Pitman Lowenthal and Sang-Yoon Lee},
  booktitle={Japanese journal of clinical oncology},
  year={2015}
}
OBJECTIVE This prospective, post-marketing study collected sunitinib safety and efficacy data in Japanese patients with unresectable/metastatic renal cell carcinoma. Retrospective analysis investigated adverse events as potential sunitinib efficacy biomarkers. METHODS Patients administered sunitinib, after its release, were registered until reaching a pre-specified number of cases. Primary starting dose was 50 mg/day orally on a 4-weeks-on and 2-weeks-off schedule. Physicians completed… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS